## Matthew W Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/989629/publications.pdf Version: 2024-02-01

		41344	29157
117	12,530	49	104
papers	citations	h-index	g-index
127	127	127	5251
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Psychedelics and health behaviour change. Journal of Psychopharmacology, 2022, 36, 12-19.	4.0	40
2	Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting Experimental and Clinical Psychopharmacology, 2022, 30, 180-193.	1.8	8
3	A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology, 2022, 36, 273-294.	4.0	28
4	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports, 2022, 9, 48-58.	3.4	7
5	At-risk drinking, operant demand, and cross-commodity discounting as predictors of drunk driving in underage college women. Behavioural Processes, 2022, 195, 104548.	1.1	2
6	Behavioral economic methods to inform infectious disease response: Prevention, testing, and vaccination in the COVID-19 pandemic. PLoS ONE, 2022, 17, e0258828.	2.5	22
7	Human behavioral pharmacology of psychedelics. Advances in Pharmacology, 2022, 93, 105-132.	2.0	6
8	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 2022, 36, 151-158.	4.0	162
9	Beyond Systematic and Unsystematic Responding: Latent Class Mixture Models to Characterize Response Patterns in Discounting Research. Frontiers in Behavioral Neuroscience, 2022, 16, 806944.	2.0	2
10	Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. Frontiers in Psychology, 2022, 13, .	2.1	41
11	Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Current Topics in Behavioral Neurosciences, 2022, , 213-227.	1.7	10
12	Attention-Deficit/Hyperactivity Disorder Symptoms Are Associated with Greater Delay Discounting of Condom-Protected Sex and Money. Archives of Sexual Behavior, 2021, 50, 191-204.	1.9	4
13	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	11.0	648
14	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 2021, 35, 353-361.	4.0	49
15	Rejecting impulsivity as a psychological construct: A theoretical, empirical, and sociocultural argument Psychological Review, 2021, 128, 336-361.	3.8	105
16	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. International Journal of Neuropsychopharmacology, 2021, 24, 615-623.	2.1	20
17	The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity Experimental and Clinical Psychopharmacology, 2021, 29, 219-228.	1.8	5
18	Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. American Journal of Drug and Alcohol Abuse, 2021, 47, 444-454.	2.1	18

#	Article	IF	CITATIONS
19	Behavioral economics and safe sex: Examining condom use decisions from a reinforcer pathology framework. Journal of the Experimental Analysis of Behavior, 2021, 116, 149-165.	1.1	10
20	Single- and cross-commodity discounting among adults who use alcohol and cannabis: Associations with tobacco use and clinical indicators. Drug and Alcohol Dependence, 2021, 229, 109082.	3.2	2
21	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy, 2021, 98, 103380.	3.3	21
22	Pharmacological assistance for psychotherapy. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100017.	1.1	0
23	Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. ACS Pharmacology and Translational Science, 2021, 4, 472-478.	4.9	51
24	Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. ACS Pharmacology and Translational Science, 2021, 4, 578-581.	4.9	55
25	Sexual discounting: A systematic review of discounting processes and sexual behavior Experimental and Clinical Psychopharmacology, 2021, 29, 711-738.	1.8	20
26	Psychedelics and Psychotherapy. Pharmacopsychiatry, 2021, 54, 167-175.	3.3	35
27	The Influence of Episodic Future Thinking and Graphic Warning Labels on Delay Discounting and Cigarette Demand. International Journal of Environmental Research and Public Health, 2021, 18, 12637.	2.6	2
28	Demographic and sexual risk predictors of delay discounting of condom-protected sex. Psychology and Health, 2020, 35, 366-386.	2.2	11
29	Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Journal of Psychopharmacology, 2020, 34, 336-347.	4.0	4
30	The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. Scientific Reports, 2020, 10, 16392.	3.3	28
31	Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology, 2020, 237, 2293-2304.	3.1	32
32	Microenterprise Intervention to Reduce Sexual Risk Behaviors and Increase Employment and HIV Preventive Practices Among Economically-Vulnerable African-American Young Adults (EMERGE): A Feasibility Randomized Clinical Trial. AIDS and Behavior, 2020, 24, 3545-3561.	2.7	5
33	Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?. Frontiers in Psychiatry, 2020, 11, 497.	2.6	4
34	The Hotel Room Purchase Task: Effects of Gender and Partner Desirability on Demand for Hypothetical Sex in Individuals with Disordered Cocaine Use and Controls. Archives of Sexual Behavior, 2020, 49, 1251-1262.	1.9	6
35	The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. Drug and Alcohol Dependence, 2020, 208, 107772.	3.2	4
36	Survey of entity encounter experiences occasioned by inhaled <i>N,N</i> -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 2020, 34, 1008-1020.	4.0	64

#	Article	IF	CITATIONS
37	Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. Journal of Psychopharmacology, 2020, 34, 654-662.	4.0	12
38	Delay and probability discounting in cocaine use disorder: Comprehensive examination of money, cocaine, and health outcomes using gains and losses at multiple magnitudes Experimental and Clinical Psychopharmacology, 2020, 28, 724-738.	1.8	14
39	Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Message Surveys in African-American Young Adults Experiencing Homelessness and Unemployment: Single-Group Study. JMIR Formative Research, 2020, 4, e14833.	1.4	2
40	Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting Experimental and Clinical Psychopharmacology, 2020, 28, 157-168.	1.8	9
41	Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices in economically-vulnerable African-American young adults (EMERGE): protocol for a feasibility randomized clinical trial. Trials, 2019, 20, 439.	1.6	11
42	Graphic Warning Labels Affect Hypothetical Cigarette Purchasing Behavior among Smokers Living with HIV. International Journal of Environmental Research and Public Health, 2019, 16, 3380.	2.6	6
43	Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 2019, 33, 1088-1101.	4.0	145
44	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 2019, 14, e0214377.	2.5	132
45	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
46	Sexual Probability Discounting: A Mechanism for Sexually Transmitted Infection Among Undergraduate Students. Archives of Sexual Behavior, 2019, 48, 495-505.	1.9	21
47	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry, 2019, 10, 955.	2.6	75
48	Working Memory Training for Adolescents With Cannabis Use Disorders: A Randomized Controlled Trial. Journal of Child and Adolescent Substance Abuse, 2018, 27, 211-226.	0.5	20
49	Perceived risk of developing smoking-related disease among persons living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1329-1334.	1.2	4
50	To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in selfâ€identified chronic pain patients. Addiction, 2018, 113, 67-79.	3.3	11
51	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 2018, 32, 49-69.	4.0	285
52	Does being drunk or high cause HIV sexual risk behavior? A systematic review of drug administration studies. Pharmacology Biochemistry and Behavior, 2018, 164, 125-138.	2.9	66
53	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology, 2018, 235, 521-534.	3.1	73
54	Psychiatry might need some psychedelic therapy. International Review of Psychiatry, 2018, 30, 285-290.	2.8	8

#	Article	IF	CITATIONS
55	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 2018, 32, 756-769.	4.0	152
56	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology, 2018, 235, 2915-2927.	3.1	58
57	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018, 142, 143-166.	4.1	184
58	Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. Addictive Behaviors, 2017, 65, 81-86.	3.0	23
59	An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 2017, 31, 841-850.	4.0	72
60	Morning administration of oral methamphetamine dose-dependently disrupts nighttime sleep in recreational stimulant users. Drug and Alcohol Dependence, 2017, 178, 291-295.	3.2	20
61	Behavioral economic substitutability of e-cigarettes, tobacco cigarettes, and nicotine gum. Journal of Psychopharmacology, 2017, 31, 851-860.	4.0	52
62	Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 2017, 14, 734-740.	4.4	180
63	Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1309-1314.	1.2	24
64	Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 2017, 117, 155-160.	2.9	54
65	Cocaine administration dose-dependently increases sexual desire and decreases condom use likelihood: The role of delay and probability discounting in connecting cocaine with HIV. Psychopharmacology, 2017, 234, 599-612.	3.1	96
66	Who is â€~Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology, 2017, 31, 1056-1060.	4.0	59
67	Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 2017, 43, 55-60.	2.1	430
68	Discounting of Condom-Protected Sex as a Measure of High Risk for Sexually Transmitted Infection Among College Students. Archives of Sexual Behavior, 2017, 46, 2187-2195.	1.9	27
69	Altered experiential, but not hypothetical, delay discounting in schizophrenia Journal of Abnormal Psychology, 2017, 126, 301-311.	1.9	15
70	Alcohol Increases Delay and Probability Discounting of Condomâ€Protected Sex: A Novel Vector for Alcoholâ€Related HIV Transmission. Alcoholism: Clinical and Experimental Research, 2016, 40, 1339-1350.	2.4	48
71	Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. Pain, 2016, 157, 1724-1732.	4.2	23
72	Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 2016, 30, 1181-1197.	4.0	1,221

#	Article	IF	CITATIONS
73	Initial feasibility and validity of a prospective memory training program in a substance use treatment population Experimental and Clinical Psychopharmacology, 2016, 24, 390-399.	1.8	5
74	Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults. Journal of Caffeine Research, 2016, 6, 10-19.	0.9	22
75	Initial examination of priming tasks to decrease delay discounting. Behavioural Processes, 2016, 128, 144-152.	1.1	15
76	Cocaine-dependent adults and recreational cocaine users are more likely than controls to choose immediate unsafe sex over delayed safer sex Experimental and Clinical Psychopharmacology, 2016, 24, 297-304.	1.8	22
77	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 2016, 30, 1268-1278.	4.0	303
78	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 2016, 30, 1279-1295.	4.0	175
79	Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 2016, 30, 323-329.	4.0	12
80	Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 250-258.	4.8	172
81	Characterizing use patterns and perceptions of relative harm in dual users of electronic and tobacco cigarettes Experimental and Clinical Psychopharmacology, 2015, 23, 494-503.	1.8	87
82	Sexual discounting among high-risk youth ages 18–24: Implications for sexual and substance use risk behaviors Experimental and Clinical Psychopharmacology, 2015, 23, 49-58.	1.8	95
83	Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence Psychology of Addictive Behaviors, 2015, 29, 237-246.	2.1	7
84	Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 2015, 29, 1041-1043.	4.0	62
85	Can psychedelic compounds play a part in drug dependence therapy?. British Journal of Psychiatry, 2015, 206, 1-3.	2.8	50
86	Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 2015, 29, 280-288.	4.0	278
87	Examining Delay Discounting of Condom-Protected Sex Among Men Who Have Sex with Men Using Crowdsourcing Technology. AIDS and Behavior, 2015, 19, 1655-1665.	2.7	37
88	Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. Journal of the Experimental Analysis of Behavior, 2015, 103, 87-107.	1.1	93
89	Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 2015, 29, 1182-1190.	4.0	318
90	A randomized controlled trial of the effects of working memory training in methadone maintenance patients. Drug and Alcohol Dependence, 2015, 156, 38-46.	3.2	79

#	Article	IF	CITATIONS
91	Nicotine reinforcement in never-smokers. Psychopharmacology, 2015, 232, 4243-4252.	3.1	21
92	Psychedelic medicine: a re-emerging therapeutic paradigm. Cmaj, 2015, 187, 1054-1059.	2.0	108
93	Cocaine dependent individuals discount future rewards more than future losses for both cocaine and monetary outcomes. Addictive Behaviors, 2015, 40, 132-136.	3.0	20
94	Delay and Probability Discounting of Sexual and Monetary Outcomes in Individuals with Cocaine Use Disorders and Matched Controls. PLoS ONE, 2015, 10, e0128641.	2.5	75
95	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews, 2015, 7, 157-164.	3.4	306
96	Examining delay discounting of condom-protected sex among opioid-dependent women and non-drug-using control women. Drug and Alcohol Dependence, 2014, 144, 53-60.	3.2	90
97	Demand curves for hypothetical cocaine in cocaine-dependent individuals. Psychopharmacology, 2014, 231, 889-897.	3.1	118
98	The Behavioral Economics of Substance Use Disorders: Reinforcement Pathologies and Their Repair. Annual Review of Clinical Psychology, 2014, 10, 641-677.	12.3	501
99	Pilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 2014, 28, 983-992.	4.0	613
100	LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods, 2013, 5, 7042.	2.7	5
101	Test–retest reliability and gender differences in the sexual discounting task among cocaine-dependent individuals Experimental and Clinical Psychopharmacology, 2013, 21, 277-286.	1.8	59
102	Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. Adolescent Psychiatry (Hilversum,) Tj ETQq0 0 0 r	gBT /Over 0.2	lock 10 Tf 50
103	An efficient operant choice procedure for assessing delay discounting in humans: Initial validation in cocaine-dependent and control individuals Experimental and Clinical Psychopharmacology, 2012, 20, 191-204.	1.8	52
104	High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, 2012, 223, 1-15.	3.1	73
105	The Sexual Discounting Task: HIV risk behavior and the discounting of delayed sexual rewards in cocaine dependence. Drug and Alcohol Dependence, 2012, 123, 15-21.	3.2	180
106	Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and Alcohol Dependence, 2012, 123, 132-140.	3.2	92
107	Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, 2012, 51, 721-737.	1.5	243
108	Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 2011, 115, 150-155.	3.2	120

#	Article	IF	CITATIONS
109	Delay discounting in current and former marijuana-dependent individuals Experimental and Clinical Psychopharmacology, 2010, 18, 99-107.	1.8	184
110	Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine Experimental and Clinical Psychopharmacology, 2010, 18, 305-315.	1.8	7
111	An algorithm for identifying nonsystematic delay-discounting data Experimental and Clinical Psychopharmacology, 2008, 16, 264-274.	1.8	423
112	Moderate drug use and delay discounting: A comparison of heavy, light, and never smokers Experimental and Clinical Psychopharmacology, 2007, 15, 187-194.	1.8	201
113	Delay discounting in currently using and currently abstinent cocaine-dependent outpatients and non-drug-using matched controls. Addictive Behaviors, 2006, 31, 1290-1294.	3.0	290
114	Ramelteon. Archives of General Psychiatry, 2006, 63, 1149.	12.3	134
115	Ramelteon. CNS Drugs, 2005, 19, 1066-1067.	5.9	1
116	Delay discounting in current and never-before cigarette smokers: Similarities and differences across commodity, sign, and magnitude Journal of Abnormal Psychology, 2003, 112, 382-392.	1.9	519
117	WITHIN-SUBJECT COMPARISON OF REAL AND HYPOTHETICAL MONEY REWARDS IN DELAY DISCOUNTING. Journal of the Experimental Analysis of Behavior, 2002, 77, 129-146.	1.1	771